Boston Scientific Corporation
BSX
Rankning i aktier
#409
Den här företagsbeskrivningen finns bara på engelska.
Boston Scientific Corporation (BSX) operates as a global leader in medical... Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
Aktiekurs
$41.88
Senast synkroniserad: 2026-10-30
Marknadsvärde
$60.69B
Förändring (1 dag)
-1.89%
Förändring (1 år)
-58.42%
Land
US
Aktiedata: Financial Modeling Prep·Uppdaterad ·Inte investeringsrådgivning·Så räknar vi
Handel Boston Scientific Corporation (BSX)
Kategori
Healthcare
Vinst för Boston Scientific Corporation (BSX)
Vinst i Sep 2026 TTM: $3.66B
Enligt de senaste finansiella rapporterna från Boston Scientific Corporation är företagets nuvarande vinst $3.66B. År 2025 hade företaget en vinst på $3.39B, en ökning jämfört med vinsten år 2024 som var $2.28B. Vinsten som visas på denna sida är vinsten före räntor och skatt, även kallad EBIT.
Vinshistorik för Boston Scientific Corporation från 2000 till 2026
Vinst vid slutet av varje år
| År | Vinst | Förändring |
|---|---|---|
| 2026 (TTM) | $3.66B | 7.98% |
| 2025 | $3.39B | 48.33% |
| 2024 | $2.28B | 14.96% |
| 2023 | $1.99B | 73.97% |
| 2022 | $1.14B | 6.04% |
| 2021 | $1.08B | -1,462.03% |
| 2020 | $-79.00M | -111.50% |
| 2019 | $687.00M | -51.69% |
| 2018 | $1.42B | 52.41% |
| 2017 | $933.00M | 427.12% |
| 2016 | $177.00M | -127.23% |
| 2015 | $-650.00M | 27.70% |
| 2014 | $-509.00M | 128.25% |
| 2013 | $-223.00M | -94.57% |
| 2012 | $-4.11B | -739.72% |
| 2011 | $642.00M | -160.40% |
| 2010 | $-1.06B | -18.73% |
| 2009 | $-1.31B | -35.60% |
| 2008 | $-2.03B | 256.94% |
| 2007 | $-569.00M | -83.90% |
| 2006 | $-3.54B | -496.75% |
| 2005 | $891.00M | -40.36% |
| 2004 | $1.49B | 132.35% |
| 2003 | $643.00M | 17.12% |
| 2002 | $549.00M | 1,147.73% |
| 2001 | $44.00M | -91.65% |
| 2000 | $527.00M | 0.00% |
Vinst för liknande företag eller konkurrenter
| Företag | Vinst | Skillnad i vinst | Land |
|---|---|---|---|
| $6.56B | 79.53% |
US
|
|
| $6.60B | 80.66% |
IE
|
|
| $5.12B | 39.97% |
US
|
|
| $3.23B | -11.70% |
DE
|
|
| $1.42B | -61.21% |
US
|
Frågor om nettoresultatet för Boston Scientific Corporation
Vad är nettoresultatet för Boston Scientific Corporation?
Enligt de senaste siffrorna (sep. 2026) är nettoresultatet för Boston Scientific Corporation $3.66B under de senaste tolv månaderna.
Vad var nettoresultatet för Boston Scientific Corporation år 2025?
År 2025 var nettoresultatet för Boston Scientific Corporation $3.39B, 48.33% högre än år 2024 ($2.28B).
Hur har nettoresultatet för Boston Scientific Corporation utvecklats sedan 2020?
Mellan 2020 och 2025 var nettoresultatet för Boston Scientific Corporation som högst år 2025 ($3.39B) och som lägst år 2020 ($-79.00M).
Hur står sig nettoresultatet för Boston Scientific Corporation jämfört med liknande bolag?
För Boston Scientific Corporation är nettoresultatet ($3.66B) högre än för 2 av de 5 liknande bolagen i listan ovan. Det högsta värdet bland dem har Medtronic plc, med $6.60B.